KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $151.4 million.

  • Supernus Pharmaceuticals' Cash & Equivalents rose 377.92% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 377.92%. This contributed to the annual value of $69.3 million for FY2024, which is 7.63% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Cash & Equivalents stood at $151.4 million, which was up 4.60% from $144.7 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Cash & Equivalents high stood at $255.6 million for Q1 2021, and its period low was $24.7 million during Q2 2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Cash & Equivalents value was $69.3 million (recorded in 2024), while the average stood at $80.1 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cash & Equivalents plummeted by 85.75% in 2023 and then skyrocketed by 377.92% in 2025.
  • Supernus Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $203.4 million in 2021, then slumped by 54.23% to $93.1 million in 2022, then declined by 19.40% to $75.1 million in 2023, then fell by 7.63% to $69.3 million in 2024, then spiked by 377.92% to $151.4 million in 2025.
  • Its Cash & Equivalents was $151.4 million in Q3 2025, compared to $144.7 million in Q2 2025 and $115.8 million in Q1 2025.